Taclonex (Calcipotriene and Betamethasone) ointment is indicated for the topical treatment of psoriasis vulgaris in adults 18 years of age and older.

Taclonex® Topical Suspension is not for oral, ophthalmic, or intravaginal use and should not be applied to the face, axillae, or groin. Do not use if atrophy is present at the treatment site.

Tweet this The LEO® Patient Assistance Program will provide Taclonex® Ointment and Taclonex Scalp® Topical Suspension at no cost to eligible plaque psoriasis patients who receive a prescription.

Two posters featuring highly significant head to head data for Wynzora® Cream (calcipotriene and betamethasone dipropionate, w/w 0.064%) vs Taclonex® Topical Suspension were shown at the Maui ...

Taclonex had sales of $135 million during the 12-month period ended in November 2010, according to Wolters Kluwer Health. Perrigo included in its application a Paragraph IV certification, a legal ...

Taclonex Topical Suspension is also indicated for the treatment of moderate to severe scalp psoriasis for up to 8 weeks in patients ≥18 years and is available in 30g, 60g, and 120g (2x60g) bottles.

PRINCETON, N.J. — Sandoz on Tuesday announced the U.S. market introduction of its calcipotriene and betamethasone dipropionate ointment, the first generic version of Leo Pharma’s Taclonex ...

Taclonex (R) Ointment and Taclonex Scalp (R) Topical Suspension can pass through your skin. Serious side effects may include too much calcium in your blood or urine or adrenal gland problems.

TACLONEX OINTMENT prescription and dosage information for physicians and health care professionals. Pharmacology, adverse reactions, warnings, and TACLONEX OINTMENTside effects.

Taclonex® Ointment (calcipotriene 0.005% / betamethasone dipropionate 0.064%) is indicated for the topical treatment of plaque psoriasis of the scalp and body in patients 18 years and older.

Taclonex is a topical ointment containing a combination of calcipotriene 0.005% and betamethasone dipropionate 0.064%, and has been cleared for the treatment of psoriasis in adults. The product is ...

MC2-01 Cream is superior to Taclonex ® based on percentage reduction in mPASI from baseline to Week 8 (64.8% versus 52.3%, p < 0.0001) (MC2-01 Cream demonstrated fast onset of action with ...